Illumina reported Q3 2024 revenue of $1.08 billion -- in line with analysts' consensus estimate. Non-GAAP EPS was $1.14, exceeding the $0.879 consensus and indicating strong cost control. Despite ...

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2024. The financial results for YTD 2024 and Q3 2023 and YTD ...

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

Oct 9 (Reuters) - Medical equipment maker Illumina (ILMN.O), opens new tab announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

每经ai快讯， 启迪药业 公告，公司于10月28日收到控股股东启迪科服发出的《告知函》，因与中国农业银行北京自贸试验区分行存在金融借款合同 ...

Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

【启迪药业：控股股东所持公司股份可能被司法拍卖 公司控制权或将变更】财联社10月29日电，启迪药业公告称，公司控股股东启迪科技服务有限 ...

11月4日，启迪环境盘中下跌2.23%，截至09:35，报2.19元/股，成交1726.21万元，换手率0.55%，总市值31.22亿元。 资金流向方面，主力 ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...